Skip to main content
  • rainbow over text: 'thank you NHS'
  • Register
  • My watchlists
  • Help
  • Contact us
  • Log out of your HL account

Oncternal Therapeutics Inc (ONCT) USD0.001

Sell:$2.91 Buy:$24.61 Change: $0.04 (1.25%)
NASDAQ:0.77%
Market closed |  Prices as at close on 27 May 2020 | Switch to live prices |
Sell:$2.91
Buy:$24.61
Change: $0.04 (1.25%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 27 May 2020 | Switch to live prices |
Sell:$2.91
Buy:$24.61
Change: $0.04 (1.25%)
Market closed |  Prices as at close on 27 May 2020 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Oncternal Therapeutics, Inc., formerly GTX, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of product candidates for the treatment of cancers. Its pipeline includes cirmtuzumab, TK-216 and chimeric antigen receptor T-cell (CAR-T). Its cirmtuzumab product candidate is an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) monoclonal antibody. Cirmtuzumab is in a Phase-I/II clinical trial in combination with ibrutinib for the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). TK216 is a small-molecule compound designed to inhibit the biological activity of E26 transformation-specific (ETS) oncoproteins. TK216 is being evaluated in combination with vincristine in a Phase-I clinical trial in patients with relapsed or refractory Ewing sarcoma. Its CAR-T product candidate targets ROR-1 and is in preclinical development as a treatment for hematologic cancers and solid tumors.

Contact details

Address:
12230 El Camino Real Ste 300
SAN DIEGO
92130-2090
United States
Telephone:
+1 (858) 4341113
Website:
www.oncternal.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ONCT
ISIN:
US68236P1075
Market cap:
$52.70 million
Shares in issue:
17.34 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • James Breitmeyer
    President, Chief Executive Officer
  • Richard Vincent
    Chief Financial Officer
  • Gunnar Kaufmann
    Chief Scientific Officer
  • Hazel Aker
    General Counsel
  • Igor Bilinsky
    Chief Business Officer
  • Frank Hsu
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.